Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches
| Autor: | Aengus O'Marcaigh, F. Breatnach, Fiona Quinn, Ann O'Meara, Prerna Tewari, Mark Lawler, Ludmila Boublikova, J Ryan, Shaun R. McCann, Paul Browne, Michael J. Neat, Owen P. Smith, Mireille Crampe, Armelle Meunier, Raymond L. Stallings |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Male medicine.medical_specialty Pathology Neoplasm Residual Adolescent Concordance Kaplan-Meier Estimate Sensitivity and Specificity Immunophenotyping hemic and lymphatic diseases Acute lymphocytic leukemia Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Prospective Studies Prospective cohort study Child Survival analysis Hematology medicine.diagnostic_test business.industry Reverse Transcriptase Polymerase Chain Reaction Infant Bone Marrow Examination Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Flow Cytometry Minimal residual disease Bone marrow examination Child Preschool Female business Follow-Up Studies |
| Zdroj: | British journal of haematology. 144(1) |
| ISSN: | 1365-2141 |
| Popis: | Summary In this single centre study of childhood acute lymphoblastic leukaemia (ALL) patients treated on the Medical Research Council UKALL 97/99 protocols, it was determined that minimal residual disease (MRD) detected by real time quantitative polymerase chain reaction (RQ-PCR) and 3-colour flow cytometry (FC) displayed high levels of qualitative concordance when evaluated at multiple time-points during treatment (93AE38%), and a combined use of both approaches allowed a multi timepoint evaluation of MRD kinetics for 90% (53/59) of the initial cohort. At diagnosis, MRD markers with sensitivity of at least 0AE01% were identified by RQ-PCR detection of fusion gene transcripts, IGH/TRG rearrangements, and FC. Using a combined RQ-PCR and FC approach, the evaluation of 367 follow-up BM samples revealed that the detection of MRD >1% at Day 15 (P =0 AE04), >0AE01% at the end of induction (P =0 AE02), >0AE01% at the end of consolidation (P =0 AE01), >0AE01% prior to the first delayed intensification (P =0 AE01), and >0AE1% prior to the second delayed intensification and continued maintenance (P =0 AE001) were all associated with relapse and, based on early time-points (end of induction and consolidation) a significant log-rank trend (P =0 AE0091) was noted between survival curves for patients stratified into high, intermediate and low-risk MRD groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text